Sort   by:  
 Page size 
UnknownCombination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Not available
S-EPMC9204428 | biostudies-literature
UnknownInfluential upregulation of KCNE4: Propelling cancer associated fibroblasts-driven colorectal cancer progression.
Not available
S-EPMC10926681 | biostudies-literature
UnknownA genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer.
Not available
S-EPMC8096820 | biostudies-literature
UnknownClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Not available
S-EPMC9205778 | biostudies-literature
UnknownPD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
Not available
S-EPMC11906745 | biostudies-literature
UnknownMouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
Not available
S-EPMC6114252 | biostudies-literature
UnknownPTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Not available
S-EPMC8738454 | biostudies-literature
UnknownGermline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Not available
S-EPMC8567649 | biostudies-literature
UnknownEffectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies.
Not available
S-EPMC11890476 | biostudies-literature
UnknownMultilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer.
Not available
S-EPMC9929250 | biostudies-literature
Sort   by:  
 Page size